Recruiting studies: B Precursor All

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
Phase 1/Phase 2 · 19 location(s) · Cellectis S.A. · NCT04150497 Blinatumomab Plus Venetoclax Sequenced With Inotuzumab Ozogamicin in Treating B-ALL
Phase 2 · 1 location(s) · First Affiliated Hospital of Zhejiang University · NCT06554626 A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic
Phase 1 · 8 location(s) · Autolus Limited · NCT06173518 Efficacy Study of Blinatumomab Clean Up Early Residual Disease for Newly Diagnosed Pediatric B Lymphoblastic Leukemia
Phase 2/Phase 3 · 4 location(s) · Shanghai Jiao Tong University School of Medicine · NCT06607419 Clinical Study of Hospital-manufactured CD19 CAR-T in Children and Adolescents With Acute Lymphoblastic Leukemia
Phase 1 · 1 location(s) · Seoul National University Hospital · NCT05210907 A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With Firs
Phase 2 · 68 location(s) · Pfizer · NCT05748171 Full-course Immunotherapy Combined With Chemotherapy in Newly Diagnosed B-cell Acute Lymphoblastic Leukemia
Phase 2 · 1 location(s) · The First Affiliated Hospital of Soochow University · NCT07564453 Bridging Allogeneic Hematopoietic Stem Cell Transplantation or Not After CD19 CAR - T (S1904) Cell Therapy for r/r B-cel
NA · 1 location(s) · Peking University People's Hospital · NCT06581081 Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL
Phase 1 · 9 location(s) · Ascentage Pharma Group Inc. · NCT04260022 CAV Regimen for R/R Ph- B-ALL
NA · 1 location(s) · The First Affiliated Hospital of Soochow University · NCT05657652 Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR
Phase 1/Phase 2 · 2 location(s) · University Hospital Heidelberg · NCT03676504 HEM-iSMART-C: Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Rela
Phase 1/Phase 2 · 33 location(s) · Princess Maxima Center for Pediatric Oncology · NCT05745714 MCW Alpha/Beta T-Cell and B-Cell Depletion With Targeted ATG Dosing
NA · 1 location(s) · Medical College of Wisconsin · NCT05794880 Study of Nutrition and Exercise in Adults Hospitalized for Treatment of Acute Lymphoblastic Leukemia (ALL)
NA · 1 location(s) · University of Chicago · NCT06785324 Blinatumomab After TCR Alpha Beta/CD19 Depleted HCT
Phase 2 · 1 location(s) · Medical College of Wisconsin · NCT04746209 Therapy for Newly Diagnosed Patients With B-Cell Precursor Acute Lymphoblastic Leukemia and Lymphoma
Phase 2 · 3 location(s) · St. Jude Children's Research Hospital · NCT06533748 4SCAR19U T Cells Targeting B Cell Malignancies
Phase 1 · 1 location(s) · Shenzhen Geno-Immune Medical Institute · NCT05995015 BCOR and ZC3H12 Genes Knock-out CD19-targeting CAR-T Cell Therapy in r/r B-ALL
Phase 1/Phase 2 · 2 location(s) · Chinese PLA General Hospital · NCT07008885 Two Step Haplo With Radiation Conditioning
Phase 2 · 1 location(s) · Thomas Jefferson University · NCT05031897 Treatment of CD19 Chimeric Antigen Receptor T Cells for Pediatric Patients With CD19-positive B-cell Acute Lymphoblastic
Phase 2 · 1 location(s) · Seoul National University Hospital · NCT06247501 A Multi-site Study to Evaluate the Persistence of Protective Immunity to Routine Childhood Vaccinations in Participants
Phase N/A · 2 location(s) · Arkansas Children's Hospital Research Institute · NCT07422337 Study of Out of Specification for Tisagenlecleucel
Phase 3 · 54 location(s) · Novartis Pharmaceuticals · NCT04094311 CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Unde
Phase 2 · 3 location(s) · City of Hope Medical Center · NCT06059391 Pilot Study of Anti-CD19 Chimeric Antigen Receptor T Cells (CAR-T Cells) for the Treatment of Relapsed/Refractory CD19+
Phase 1 · 1 location(s) · University of Utah · NCT06227026 A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acu
Phase 2 · 225 location(s) · National Cancer Institute (NCI) · NCT04546399 Effectiveness and Safety of Tisagenlecleucel Therapy in Brazilian Patients With B-lymphocyte Malignancies
Phase N/A · 7 location(s) · Novartis Pharmaceuticals · NCT05541341 Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
Phase 1 · 31 location(s) · Therapeutic Advances in Childhood Leukemia Consortium · NCT05476770 CART19 Cells Effects in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Non-Hodgkin's Lymphoma
Phase 1 · 1 location(s) · Institute of Hematology and Blood Transfusion, Czech Republi · NCT05054257 CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory
Phase 1/Phase 2 · 1 location(s) · National Cancer Institute (NCI) · NCT05442515 Nanobody-Based CD19/CD22 Tandem Dual CAR-T Therapy for R/R B-ALL
Phase 1/Phase 2 · 1 location(s) · Peking University People's Hospital · NCT06880913

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →